Tercica Somatuline Autogel Launch Planned For 2007 Pending NDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Tercica’s partner, Ipsen, submitted an NDA for the acromegaly treatment Oct. 30.
You may also be interested in...
Tercica Acromegaly Therapy Will Launch In Two Months
Based on firm's $100 million sales projections, Somatuline Depot likely will be priced at $25,000 per patient.
Tercica Acromegaly Therapy Will Launch In Two Months
Based on firm's $100 million sales projections, Somatuline Depot likely will be priced at $25,000 per patient.
Tercica To Pursue Development Of Nutropin AQ/Increlex Combination Products
Deal with Genentech calls for development of drugs for short stature, adult growth hormone deficiency and potentially metabolic disorders.